Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-negative Breast Cancer
Interventions: DRUG: Surufatinib|DRUG: Tislelizumab
Sponsor: Huihua Xiong